Thrombophilia testing in VTE should be individualized and guided by clinical context, guideline recommendations, and ethnic variations to ensure results meaningfully influence management decisions.
Answers are grounded in this paper and cite their sources.
Supports selective testing in high-risk VTE; leaves open prospective validation of management impact.
Deep vein thrombosisVenous thromboembolism Thrombophilia Antiphospholipid syndrome Ethnic and racial minorities Venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary embolism, remains a major cause of morbidity and mortality.In carefully selected patients, evaluation for inherited or acquired thrombophilia can offer valuable insights for individualized management and recurrence prevention.Current international guidelines recommend targeted thrombophilia testing only in cases of unprovoked or recurrent VTE, early-onset disease, strong family history, or thrombosis at unusual sites.Clinically relevant tests include Factor V Leiden, Prothrombin G20210A, and deficiencies of antithrombin, protein C, and protein S, as well as antiphospholipid antibodies.The prevalence and clinical impact of inherited thrombophilias differ across populations; mutations such as Factor V Leiden and Prothrombin G20210A are rare in East Asians, whereas natural anticoagulant deficiencies and antiphospholipid syndrome are more significant.Thrombophilia testing should therefore be individualized and guided by clinical context, ensuring that results meaningfully influence management decisions.Recognition of ethnic variation and adherence to evidence-based diagnostic strategies can enhance precision in the prevention and treatment of VTE.
No takes yet. Share an insight, caveat, or question.
Shin et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: